Jefferies provided color on Ariad Pharmaceuticals ARIA. In a research report published today, Jefferies commented on the company's ridaforolimus drug testing process.
In the report, Jefferies states, "ARIA presented updated ridaforolimus OS data yesterday at ASCO in bone and
soft tissue sarcoma from Phase 3 trial (SUCCEED) shows a continued trend in
overall survival (OS) benefit of 21.4 months vs. 19.2 months for placebo (386
events, HR=0.88, p=0.2256)."
At the moment, Jefferies has a Buy rating and a price target of $11 on the company's stock. On Monday, Ariad added 0.25% to its value to close the day at $7.91.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in